ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
Filed with ASX · · 5 pages · English
Story so far
Earlier from Noxopharm
- FDA allows Veyonda Pre-IND Submission for COVID-19
- Entitlement Offer Prospectus
- $7.9 Million Fully Underwritten Entitlement Offer Announced
- Noxopharm March 2020 Quarterly Report & Appendix 4C
- Abscopal Responses Achieved in Prostate Cancer
Later from Noxopharm
- Pro-rata Non-Renounceable Rights Issue Fully Allocated
- COVID-19 Trial Program to Commence in Europe
- Data Shows Idronoxil Holds Key to Problem of COLD Cancers
- Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’ Tumors to ‘Hot’
- Noxopharm 2020 June quarter Appendix 4C & Activities Report
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm